Biotechnology Following Regeneron Pharmaceuticals’ announcement that the US Food and Drug Administration had issued a complete response letter (CRL) regarding its supplemental Biologics License Application (sBLA) of the 12-week injection dosing for Eylea (aflibercept) in patients with wet age-related macular degeneration (wet AMD), the labeling issue will likely heat already anticipated competition with rival Novartis’ new wet AMD drug, brolucizumab, which is yet to be approved for marketing. 17 August 2018